In this study, we applied this approach to induce immune tolerance by converting pathogenic CD4+ T cells into Foxp3+ Tregs, thereby extending the therapeutic potential of AP-EVs from cancer to autoimmune and allergic diseases. Here, FOXP3 is linked to allergic disease.